



61

AFW  
1635

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Gleave, et al.

Application No.: 09/944,326

Filed: 8/30/2001

Title: TRPM-2 Antisense Therapy

Attorney Docket No.: UBC.P-020-2

Group Art Unit: 1635

Examiner: Tracy Ann Vivlemore

Assistant Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants request that the references listed on form PTO 1449, which is attached, be made of record in the US Patent and Trademark Office in the file relating to the above-captioned application. Copies of the listed references are enclosed.


Applicants enclose the fee for submission of this IDS. The Commissioner is authorized to charge any fees due in connection with this paper or credit any overpayment to Deposit Account No. 15-0610.

03/28/2005 HMARZI1 00000024 09944326

01 FC:1806


180.00 OP

Respectfully Submitted,



Marina T. Larson  
Marina T. Larson, Ph.D  
Attorney/Agent for Applicant(s)  
Reg. No. 32038

(970) 468 6600



## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*


Application Number	09/944,326
Filing Date	8/30/2001
First Named Inventor	Gleave et al.
Art Unit	1635
Examiner Name	Tracy Ann Vivemore
Attorney Docket Number	UBC-P-020-2

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of US PTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	09/944,326
Filing Date	8/30/2001
First Named Inventor	Gleave et al.
Art Unit	1635
Examiner Name	Tracy Ann Vivlemore
Attorney Docket Number	UBC.P-020-2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		AGRAWAL ET AL., Antisense Therapeutics: is it as simple as complementary base recognition, Molecular Medicine Today, 2000, Page(s) 72-81, Volume 6, Publisher: Elsevier Science Ltd.	
		ANDREA D. BRANCH, A good antisense molecule is hard to find, TIBS, 1998, Page(s) 45-50, Publisher: Elsevier Science Ltd.	
		CROOKE ET AL., Basic Principles of Antisense Therapeutics, Antisense Research and Application, 2004, Page(s) 1-50, Publisher: Springer	
		JEN ET AL., Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies, Stem Cells 2000, 2000, Page(s) 307-319, Volume 18	
		OPALINSKA ET AL., Nucleic-acid therapeutics: Basic principles and recent applications, Nature Reviews, 2002, Page(s) 503-514, Volume 1	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.